share_log

C4 Therapeutics | 10-Q: Q2 2024 Earnings Report

C4 Therapeutics | 10-Q: Q2 2024 Earnings Report

C4 Therapeutics | 10-Q：2024财年二季报
美股sec公告 ·  08/01 07:31
Moomoo AI 已提取核心信息
C4 Therapeutics, a clinical-stage biopharmaceutical company, has not reported any revenue as of June 30, 2024, with its financial performance primarily driven by collaboration agreements. The company has ongoing agreements with Roche, Biogen, and Calico, focusing on the development of treatments for cancer and neurological conditions. Under the Roche Agreement, C4 Therapeutics received an upfront payment of $40 million and may receive milestone payments up to $273 million, plus royalties on net sales. The company also has a collaboration with Biogen for novel treatments for neurological conditions, with potential milestone payments of up to $35 million per target. The Calico Agreement, which ended in March 2023, could yield up to $132 million in development and commercial milestone payments. Revenue from these collaborations for the first half of 2024 totaled $15.045 million, a significant increase from $6.423 million in the same period of 2023. The company's future plans include advancing clinical trials for its product candidates, such as cemsidomide for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
C4 Therapeutics, a clinical-stage biopharmaceutical company, has not reported any revenue as of June 30, 2024, with its financial performance primarily driven by collaboration agreements. The company has ongoing agreements with Roche, Biogen, and Calico, focusing on the development of treatments for cancer and neurological conditions. Under the Roche Agreement, C4 Therapeutics received an upfront payment of $40 million and may receive milestone payments up to $273 million, plus royalties on net sales. The company also has a collaboration with Biogen for novel treatments for neurological conditions, with potential milestone payments of up to $35 million per target. The Calico Agreement, which ended in March 2023, could yield up to $132 million in development and commercial milestone payments. Revenue from these collaborations for the first half of 2024 totaled $15.045 million, a significant increase from $6.423 million in the same period of 2023. The company's future plans include advancing clinical trials for its product candidates, such as cemsidomide for multiple myeloma and non-Hodgkin lymphomas, and CFT1946 for BRAF V600X mutant solid tumors.
临床阶段生物医药公司c4 therapeutics截至2024年6月30日尚未报告营业收入，其业绩主要来源于合作协议。该公司与Roche、渤健公司和Calico签订了持续的合作协议，专注于癌症和神经系统疾病治疗的开发。根据与Roche签订的协议，c4 therapeutics获得了4000万美元的首付款，并可能获得高达27300万美元的阶段性付款和净销售额的特许权使用费。该公司还与渤健公司合作研发新型神经系统疾病治疗，每个目标的潜在阶段付款高达3500万美元。Calico协议于2023年3月结束，开发和商业化阶段的里程碑支付最高可达13200万美元。截至2024年上半年，这些合作协议的收入总计为1504.5万美元，大幅增长，高于2023年同期的642.3万美元。该公司未来计划包括推进其产品候选的临床试验，例如治疗多发性骨髓瘤和非何杰金淋巴瘤的Cemsidomide以及用于BRAF V600X突变实体瘤的CFT1946。
临床阶段生物医药公司c4 therapeutics截至2024年6月30日尚未报告营业收入，其业绩主要来源于合作协议。该公司与Roche、渤健公司和Calico签订了持续的合作协议，专注于癌症和神经系统疾病治疗的开发。根据与Roche签订的协议，c4 therapeutics获得了4000万美元的首付款，并可能获得高达27300万美元的阶段性付款和净销售额的特许权使用费。该公司还与渤健公司合作研发新型神经系统疾病治疗，每个目标的潜在阶段付款高达3500万美元。Calico协议于2023年3月结束，开发和商业化阶段的里程碑支付最高可达13200万美元。截至2024年上半年，这些合作协议的收入总计为1504.5万美元，大幅增长，高于2023年同期的642.3万美元。该公司未来计划包括推进其产品候选的临床试验，例如治疗多发性骨髓瘤和非何杰金淋巴瘤的Cemsidomide以及用于BRAF V600X突变实体瘤的CFT1946。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息